Condition: Sickle Cell Disease · Acute Chest Syndrome · Sponsor: Assistance Publique - Hôpitaux de Paris
The purpose of this study is to determine whether a single infusion of tocilizumab is effective in reducing the time to successful weaning from both supplemental oxygen and any respiratory support, in pediatric and adult patients with sickle cell disease (SCD) during acute chest syndrome (ACS).
This description comes directly from the study's public registry record.
Slimane ALLALI, MD, PhD · 01 44 49 48 96 · slimane.allali@aphp.fr
Aminata TRAORE, Project advisor · aminata.traore@aphp.fr
Always discuss trial participation with your own doctor first.
| Department of General Pediatrics and Sickle Cell Center, Necker-Enfants malades Hospital | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06818266